Log In
BCIQ
Print this Print this
 

VR2076 (formerly SKP-2076)

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
DescriptionAn inhaled corticosteroid (ICS), long-acting muscarinic receptor antagonist (LAMA) and long-acting adrenergic receptor beta 2 agonist (LABA) fixed-dose combination product in a pressurized metered dose inhaler (pMDI)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationAsthma
Indication DetailsTreat asthma
Regulatory Designation
PartnerMundipharma International Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$634.2M

$100.6M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/10/2016

$634.2M

$100.6M

0

12/23/2015

Undisclosed

0

Undisclosed

Get a free BioCentury trial today